Heart transplant trial seeks safer way to block dangerous virus
NCT ID NCT07079735
Summary
This study aims to find the best drug to prevent a common and serious viral infection called CMV in people who have received a heart transplant. Researchers will compare the standard drug, valganciclovir, with a newer one called letermovir to see which one is safer and more effective at keeping the virus under control. The main goal is to see if the newer drug causes fewer side effects related to low white blood cell counts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV VIREMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University/NYP Milstein Hospital
RECRUITINGNew York, New York, 10032, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NYP-Weill Cornell
RECRUITINGNew York, New York, 10021, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.